Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Apr;40(4):615-35.
doi: 10.1007/s00259-012-2295-5. Epub 2012 Dec 12.

Value of 11C-methionine PET in imaging brain tumours and metastases

Andor W J M Glaudemans  1 , Roelien H Enting, Mart A A M Heesters, Rudi A J O Dierckx, Ronald W J van Rheenen, Annemiek M E Walenkamp, Riemer H J A Slart
Affiliations
Review

Value of 11C-methionine PET in imaging brain tumours and metastases

Andor W J M Glaudemans et al. Eur J Nucl Med Mol Imaging. 2013 Apr.

Abstract

(11)C-methionine (MET) is the most popular amino acid tracer used in PET imaging of brain tumours. Because of its characteristics, MET PET provides a high detection rate of brain tumours and good lesion delineation. This review focuses on the role of MET PET in imaging cerebral gliomas. The Introduction provides a clinical overview of what is important in primary brain tumours, recurrent brain tumours and brain metastases. The indications for radiotherapy and the results and problems arising after chemoradiotherapy in relation to imaging (pseudoprogression or radionecrosis) are discussed. The working mechanism, scan interpretation and quantification possibilities of MET PET are then explained. A literature overview is given of the role of MET PET in primary gliomas (diagnostic accuracy, grading, prognosis, assessment of tumour extent, biopsy and radiotherapy planning), in brain metastases, and in the differentiation between tumour recurrence and radiation necrosis. Finally, MET PET is compared to other nuclear imaging possibilities in brain tumour imaging.

PubMed Disclaimer

References

    1. Lancet Neurol. 2009 Sep;8(9):810-8 - PubMed
    1. Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):2082-7 - PubMed
    1. Lancet Oncol. 2008 May;9(5):453-61 - PubMed
    1. Neurologist. 2003 Jul;9(4):180-8 - PubMed
    1. Eur Neurol. 1993;33(3):248-51 - PubMed